Report on the Unemployment Insurance Tax Redesign Project administered by Iowa Workforce Development for the period July 1, 2002 through June 30, 2009

Report on the Unemployment Insurance Tax Redesign Project administered by Iowa Workforce Development for the period July 1, 2002 through June 30, 2009

Insurance and Welfare Benefits Education Report 2007

The following report is a summary of the insurance and welfare benefits education activities in 2007. 2007 was the first full year that DAS-HRE had a full-time health and welfare benefits educator.

Audit report on the Northeast Iowa Schools Insurance Trust for the year ended June 30, 2009

Audit report on the Northeast Iowa Schools Insurance Trust for the year ended June 30, 2009

Iowa Insurance Division Report to the Governor for Year End 2001

Iowa Insurance Division Report to the Governor for Year End 2001

Iowa Insurance Division Report to the Governor for Year End 2002

Iowa Insurance Division Report to the Governor for Year End 2003

Iowa Insurance Division Report to the Governor for Year End 2003

Iowa Insurance Division Report to the Governor for Year End 2003

Iowa Insurance Division Report to the Governor for Year End 2004

Iowa Insurance Division Report to the Governor for Year End 2004

Iowa Insurance Division Report to the Governor for Year End 2005

Iowa Insurance Division Report to the Governor for Year End 2005

Iowa Insurance Division Report to the Governor for Year End 2006

Iowa Insurance Division Report to the Governor for Year End 2006

Iowa Insurance Division Report to the Governor for Year End 2007

Iowa Insurance Division Report to the Governor for Year End 2007

Iowa Insurance Division Report to the Governor for Year End 2008

Iowa Insurance Division Report to the Governor for Year End 2008

Whole-cell bioprocessing of human fetal cells for tissue engineering of skin.

Current restrictions for human cell-based therapies have been related to technological limitations with regards to cellular proliferation capacity (simple culture conditions), maintenance of differentiated phenotype for primary human cell culture and transmission of communicable diseases. Cultured primary fetal cells from one organ donation could possibly meet the exigent and stringent technical aspects for development of therapeutic products. Master and working cell banks from one fetal organ donation (skin) can be developed in short periods of time and safety tests can be performed at all stages of cell banking. For therapeutic use, fetal cells can be used up to two thirds of their life-span in an out-scaling process and consistency for several biological properties includes protein concentration, gene expression and biological activity. As it is the intention that banked primary fetal cells can profit from the prospected treatment of hundreds of thousands of patients with only one organ donation, it is imperative to show consistency, tracability and safety of the process including donor tissue selection, cell banking, cell testing and growth of cells in out-scaling for the preparation of whole-cell tissue-engineering products.